Read-Gene (RDG) Stock Overview
Engages in the detection, prevention, and treatment of various types of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
RDG Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Read-Gene S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł5.30 |
| 52 Week High | zł6.90 |
| 52 Week Low | zł3.92 |
| Beta | 0.50 |
| 1 Month Change | -2.21% |
| 3 Month Change | -3.64% |
| 1 Year Change | 22.12% |
| 3 Year Change | 60.61% |
| 5 Year Change | 55.88% |
| Change since IPO | 96.30% |
Recent News & Updates
Recent updates
Is Read-Gene (WSE:RDG) Using Too Much Debt?
Jan 17
Read-Gene (WSE:RDG) Is Carrying A Fair Bit Of Debt
Nov 27Does Read-Gene (WSE:RDG) Have A Healthy Balance Sheet?
Jul 17Read-Gene (WSE:RDG) Is Making Moderate Use Of Debt
Feb 14Read-Gene S.A.'s (WSE:RDG) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Dec 17
Shareholder Returns
| RDG | PL Biotechs | PL Market | |
|---|---|---|---|
| 7D | -0.4% | -4.2% | -3.6% |
| 1Y | 22.1% | -6.0% | 14.0% |
Return vs Industry: RDG exceeded the Polish Biotechs industry which returned -6% over the past year.
Return vs Market: RDG exceeded the Polish Market which returned 16.2% over the past year.
Price Volatility
| RDG volatility | |
|---|---|
| RDG Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in PL Market | 11.2% |
| 10% least volatile stocks in PL Market | 3.3% |
Stable Share Price: RDG's share price has been volatile over the past 3 months compared to the Polish market.
Volatility Over Time: RDG's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Polish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 20 | Jan Lubinski | www.read-gene.com |
Read-Gene S.A. engages in the detection, prevention, and treatment of various types of cancer. Its activities include chemoprevention, clinical tests, and genetic tests. The chemoprevention segment engages in the use of natural or synthetic substances to inhibit, reverse, or delay the process of cancer.
Read-Gene S.A. Fundamentals Summary
| RDG fundamental statistics | |
|---|---|
| Market cap | zł62.49m |
| Earnings (TTM) | zł808.33k |
| Revenue (TTM) | zł15.57m |
Is RDG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RDG income statement (TTM) | |
|---|---|
| Revenue | zł15.57m |
| Cost of Revenue | zł1.00m |
| Gross Profit | zł14.57m |
| Other Expenses | zł13.76m |
| Earnings | zł808.33k |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 13, 2026
| Earnings per share (EPS) | 0.069 |
| Gross Margin | 93.56% |
| Net Profit Margin | 5.19% |
| Debt/Equity Ratio | 217.0% |
How did RDG perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/24 10:30 |
| End of Day Share Price | 2026/03/24 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Read-Gene S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.